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INTRODUCTION
Alcohol dehydrogenases (ADHs; EC 1.1.1.1) are enzymes able to reversibly oxidize of a wide variety of endogenous and xenobiotic alcohols to the corresponding aldehydes (1) .
Mammals have evolved different ADHs that can be grouped into five classes based on similarities in amino acid sequences and biochemical properties (2) . Class I ADH (ADH1) constitutes the classical hepatic form that accounts for most of the ethanol-oxidizing capacity in the liver (3) . Only one ADH1 enzyme and gene (Adh1) is found in the mouse and rat. By contrast, humans have three class I ADHs (ADH1A, ADH1B and ADH1C; traditionally designated , , and  isoenzymes, respectively) that are encoded by unique genes that are clustered head-to-tail within an 80 kb on chromosome 4 and are very similar to each other in the exon-intron structure and nucleotide sequences (1) . All three human ADH1 enzymes are highly expressed in the adult liver and at lower levels in a variety of extrahepatic tissues (4) . A different pattern of temporal expression for each of the three isoenzymes have been observed during liver development (4) . Considerable efforts have been devoted to identify the factors involved in controlling human class I ADH gene expression, most of them focused on the analysis of tissue specific and temporal regulation. The three ADH1 genes share 80-84% sequence identity for about 270 bp upstream of the transcription start site, and significant similarity among them extends to -795 bp (5) . However, in vitro binding analysis and transfection studies in liver and non-liver cancer cell lines revealed regulatory sequences mediating differential transcriptional mechanisms for each of the ADH1 genes to account for the distinct expression patterns (6) . Thus, transcription factors CCAAT/enhancer-binding protein  (C/EBP), C/EBP and HNF-1 were found to selectively contribute to the liver specific expression and the induction of each of the ADH1 genes during liver development (7, 8) .
Bile acids may function as signaling molecules in regulating their own synthesis and transport and controlling lipid and glucose homeostasis (9) . Bile acid signaling in the liver is mostly mediated via the farnesoid X receptor  (FXR; NR1H4, hereafter referred as FXR), a member of the nuclear receptor superfamily of ligand-activated transcription factors (10) . FXR heterodimerizes with the retinoid X receptor (RXR) and binds to consensus sequences, most commonly an IR1 (inverted hexameric nucleotide repeat separated by one nucleotide), and, in the presence of specific agonists, activates transcription of target genes involved in bile acid, cholesterol, lipoprotein, and glucose metabolism (10) . FXR has been shown to have relevance in the attenuation of clinically important conditions such as gallstone disease (11, 12) , cholestasis (13) , and fatty liver disease (14) . Most of these hepatoprotective functions of FXR can be attributed to the induction of genes involved in bile acid detoxification and xenobiotic metabolism, including phase I oxidation enzyme CYP3A4 (15) , and a number of phase II conjugation enzymes (16) , and phase III efflux transporters (10) .
In addition to the rate-limiting step in ethanol metabolism, human ADH1 isoenzymes catalyze steps in several metabolic pathways including vitamin A (retinol) oxidation, which is the rate-limiting step in the conversion of retinol to retinoic acid (17) , and, interestingly, bile acid metabolism. Thus, ADH1B has been shown to oxidize the bile alcohol 5-cholestane-3, 7, 12, 26-tetrol to the 3, 7, 12-trihydroxy-5-cholestanoic acid, an intermediate in bile acid synthesis (18) , whereas ADH1C was identified as the sole bile acid 3-hydroxysteroid dehydrogenase present in human liver citosol that promotes epimerization of iso bile acids to 3-hydroxy bile acids, which are subsequently secreted by hepatocytes into bile (19, 20) . In this study, we investigated the effect of both the endogenous bile acid chenodeoxycholic acid (CDCA) and synthetic FXR agonist GW4064 on class I ADH gene expression. The data presented herein identify the nuclear receptor FXR as a regulator of human ADH1 genes, thus linking bile acid signaling and alcohol metabolism.
MATERIALS AND METHODS

Animal Experiments
Experimental protocols with mice were performed with the approval of the animal ethics committee of the University of Barcelona (Spain). 10-week-old male C57BL/6 were injected intraperitoneally with either vehicle (corn oil 5% DMSO) or GW4064 (GlaxoSmithKline, RTP, NC) dissolved in vehicle (10 mg/ml) at a dose of 50 mg/kg. After 8 h, mice were sacrificed, and livers were excised, snap-frozen in liquid nitrogen, and stored at -80 ºC until analysis.
Cell Culture and Treatment Conditions
Human hepatoma HepG2 and Huh7 cells and rat hepatoma FAO cells were cultured in DMEM supplemented 10% FBS. Primary mouse hepatocytes were isolated by the collagenase method as previously described (21) and cultured for 6 h before treatments. Human primary hepatocytes were obtained commercially (Ready Heps 
RNA Isolation and Real-time Quantitative PCR Analysis
Total RNA was isolated from cells or livers by using Tri-Reagent (Ambion) and further treated with DNase I (Ambion). cDNA was synthesized from total RNA (1 g) by murine leukemia virus reverse transcriptase (Invitrogen) and p(dN) 6 
Small Interfering RNA Transfection
The human FXR siGENOME SMARTpool (M-003414-01) or siGENOME Non- h, followed by 24 h of treatments as described above.
Adenoviral Infection
Huh7 cells were infected at a multiplicity of infection of 25 or 50 for 48 h with adenoviruses expressing VP16 (AdVP16) or VP16FXR chimeras (AdVP16FXR) previously described (22) .
Plasmids
The ADH1A proximal promoter (-1877 to +78 relative to the transcription start site) was amplified by PCR from genomic DNA using primers 5'-agtcacgcgtggagctaggtatagttgatg-3' and 5'-agtcctcgagtccttgtggatttcttcc-3', MluI/XhoI digested, and subcloned into pGL3-basic vector (Promega) to generate pGL3-ADH1A. Similarly, the ADH1B promoter (-2850 to +59) was amplified using primers 5'-agtcggtaccattattctgcctagcacacc-3' and 5'-agtcgctagcagactgtgagtctttgtgg-3', while the ADH1C promoter (-2519 to +35) was amplified using primers 5'-agtcggtacctcgtactatccctgattgg-3' and 5'-agtcgctagcttcttctctgcttgagtgc-3', and the PCR products were subcloned into KpnI/NheI sites of the pGL3bv to generate pGL3-ADH1B
and pGL3-ADH1C, respectively. Mutagenesis were performed using QuickChange TM sitedirected mutagenesis kit (Stratagene) and oligonucleotides containing mutations corresponding, respectively, to nt -97A→G/-92C→G/-91C→G of ADH1A promoter, nt -120A→G/-115C→G/-114C→G of ADH1B promoter, and nt -122G→A/-121G→T/-115A→T/-114T→C of ADH1C
promoter. The reporter plasmids pADH1AIR1-TK, pADH1BIR1-TK, and pADH1CIR1-TK were generated by insertion of 4 copies of a double-stranded oligonucleotide containing sequences spanning nt -108 to -82 of ADHA1 (5'-gatccattgctggttcattgccctcttcttta-3'), nt -131 to -106 of ADH1B (5'-gatccattgctggttcagtacccttttatcta-3'), or nt -133 to -107 of ADH1C (5'-gatccagtgctggttcggtgcccatttcttta-3'), into the BglII site of pGL3-TK (23) . Plasmids expressing human retinoid X receptor  (RXR, NR2B1) and FXR into pSG5 have been described (23) .
Cell Transfection and Reporter Assays
Huh7 cells were transiently transfected as previously described (23) . After 6h, cells were treated for 24 h with the vehicle (DMSO), 100 M CDCA, or 1 M GW4064 as described above. Luciferase activities were assayed as previously described (23) . All transfections were performed in triplicate, and similar results were obtained in at least three independent experiments.
Western Blot Analysis
Whole protein cell extracts were obtained from Huh7 cells in Nonidet P-40 lysis buffer 
In Silico Analysis of FXR Response Elements (FXREs)
The analysis of genomic sequences for the identification of putative FXREs was performed using the NUBIScan computer algorithm (www.nubiscan.unibas.ch/).
In Vitro Transcription/Translation and Electrophoretic Mobility Shift Assay (EMSA)
Double-stranded oligonucleotides corresponding to the sequences spanning nt -108 to -82 of ADHA1, nt -131 to -106 of ADH1B, or nt -133 to -107 of ADH1C were radiolabeled and used in EMSA as previously described (23) . A probe containing the FXRE of the human ileal-bile acid-binding protein (I-BABP) gene promoter was used as a control. For competition experiments, increasing fold molar excess of unlabeled probes were included during a 15 min preincubation on ice. The probe mutADH1AIR1 corresponds to the sequence spanning nt -108 to -82 of ADHA1 harboring mutations in nt -97A→G/-92C→G/-91C→G.
Alcohol Dehydrogenase Activity Assay
ADH enzymatic activity was determined using Alcohol Dehydrogenase Assay Kit (cat# K787, BioVision, Milpitas, CA) following manufacturer's instruction, and normalized to protein content in each sample.
Statistical Analysis
Data are expressed as mean ± SEM as determined by analysis of multiple independent samples, as indicated in figure legends. Significant differences were assessed using a two-tailed Student's t test. Values of p < 0.05 were considered to be significant.
RESULTS
Class I ADH Gene Expression is Induced in Human Primary Hepatocytes and Hepatoma
Cell Lines in Response to FXR Ligands
Inasmuch as FXR regulates the expression of genes involved in detoxification and drug metabolism (15, 16) , and because class I ADH enzymes are reported to take part in bile acid metabolism (18) (19) (20) , we evaluated whether this nuclear receptor modulates class I ADH gene expression. Human primary hepatocytes were exposed for 24 h to CDCA, a natural bile acid agonist of FXR, or GW4064, a synthetic and specific FXR agonist, and analyzed for the expression of the three ADH1 genes. As illustrated in Fig. 1A , both FXR ligands significantly increased ADH1A and ADH1B mRNA levels. As expected, the well characterized FXR target gene PLTP (24) was also induced when primary human hepatocytes were treated with FXR agonists. In contrast, ADH1C mRNA were not induced after activation of FXR (Fig. 1A ). To confirm these results in human hepatoma cell lines, HepG2 cells were also incubated in the presence of vehicle (DMSO) or FXR agonists. Again, no significant induction of ADH1C was observed in response to FXR ligands, whereas ADH1A and ADH1B mRNA levels were strongly increased ( Fig. 1B) . In addition, FXR activation failed to induce cytochrome P450 2E1 (CYP2E1), cytosolic aldehyde dehydrogenase (ALDH1A1), or mitochondrial aldehyde dehydrogenase (ALDH2) mRNA levels. Next, Western blot analyses performed on cell lysates from Huh7 treated with FXR agonists revealed that the quantity of ADH1 protein was robustly increased, compared to cells receiving vehicle (Fig. 1C) .
Overexpression of Constitutively Active FXR Increases ADH1A and ADH1B mRNA Levels
To further confirm the role of FXR in the regulation of the ADH1 gene cluster, we performed gain-of-function studies by ectopically expressing a constitutively active form of FXR (VP16FXR) (22) in Huh7 cells. The expression of ADH1A and ADH1B, but not ADH1C, was induced by FXR overexpression (Fig. 2) . Collectively, these data suggest that FXR induces specifically the expression of ADH1A and ADH1B isoenzymes.
The Inductions of ADH1A and ADH1B by CDCA and GW4064 Require FXR Expression
Since bile acids may exert their signaling actions through FXR-independent pathways (9,25), we silenced FXR by siRNA to ascertain whether the inductions observed upon treatment with CDCA were dependent on FXR. Therefore, Huh7 were transfected with non-targeting siRNA or siRNA complexes directed against FXR (siFXR) before treatments. siFXR-mediated knock-down of endogenous FXR levels ( Fig. 3A) almost completely eliminated the induction of ADH1A and ADH1B by bile acid CDCA (Fig. 3B) . As a control, CDCA-dependent induction of NR0B2 (hereafter referred as SHP), a well known FXR target gene (10), was similarly attenuated in siFXR-transfected cells. Likewise, as depicted in Fig. 3C , we also confirmed by FXR knockdown the requirement of FXR in the responses of these genes to GW4064 to rule out any effect of this synthetic ligand that could relate to weak agonistic effects on other receptors (26) .
FXR Regulation of Class I ADH Does Not Occur in Rodents
To examine whether FXR regulation of ADH1 also occurs in rodents, C57BL/6 mice were treated with either vehicle or FXR agonist GW4064 and analyzed for hepatic transcript levels. Unexpectedly, no significant change of Adh1 mRNA levels was observed following activation FXR, in spite of the marked induction of the known FXR target Shp (Fig. 4A) . To exclude the possibility that the dissimilar findings in human hepatocytes and in mouse liver were attributable to methodological differences, mouse primary hepatocytes were incubated in the presence of vehicle or GW4064. Again, Shp was highly induced after FXR activation, whereas no significant change was detected in Adh1 transcript levels (Fig. 4B) . Likewise, analyses performed on rat hepatoma FAO cells treated with CDCA, GW4064, or vehicle showed induction of Shp in response to FXR ligands but no change in rat Adh1 transcript levels (Fig.   4C ). Taken together, these data indicate that induction of class I ADH genes by activation of FXR is species specific since it was observed in human but not in rodent-derived hepatocytes.
Identification and Functional Characterization of Putative FXREs in the Promoters of
ADH1 Genes
In order to determine whether FXR directly controls ADH1 expression and also with the aim to understand the molecular mechanisms involved in the differences observed in the FXR dependent regulation of the distinct human ADH1 genes, the promoters of ADH1A, ADH1B and ADH1C were in silico analyzed for putative FXREs using the NUBIScan computer algorithm.
Most known FXREs consist of an IR of the RGGTCA hexad with minor variants (27, 28) .
Accordingly, an IR1 motif was identified as a putative FXRE in the proximal promoter of each of the three genes. As illustrated in Fig. 5A , IR1 elements in ADH1A, ADH1B and ADH1C promoters differ from 2, 3 and 4 nucleotides, respectively, from the consensus FXRE. The presence of a T at position 3 and a C at position 10 of the IR1 element are permissive (e.g.
FXREs of FGF19 and ALAS1, respectively) (10, 29) . In contrast, A into G conversion at the sixth position, as it occurs in the ADH1C element, is detrimental to receptor binding (27, 28) . To determine if the ADH1 proximal promoters were able to confer a response to FXR, we performed transient transfection assays in Huh7 cells with luciferase reporter constructs under the control of ~2-2.9 kb fragments corresponding to ADH1 gene promoters in the presence or absence of a plasmid encoding FXR and the agonist GW4064. The data in Fig. 5B show that reporter activity of ADH1A and ADH1B promoter constructs was increased by activated FXR, whereas no significant effects were observed on the ADH1C promoter construct or the promoterless pGL3 basic vector. These results are consistent with the higher similarity of ADH1A and ADH1B IR1 elements to the consensus FXRE. To further confirm this observation, the IR1 element for each promoter was cloned upstream of the thymidine kinase promoter-driven luciferase reporter gene.
As expected, transient transfection assays showed that the reporter constructs containing the IR sequences of ADH1A or ADH1B, but not of ADH1C, were strongly transactivated by FXR (Fig.   5C ).
To assess the importance of the identified IR1 elements in FXR-dependent activation, we introduced single nucleotide mutations to disrupt the IR1 in the context of ADH1 promoters to generate pGL3-ADH1Amut and pGL3-ADH1Bmut constructs, respectively. As depicted in Fig   5D , these point mutations completely abrogated the response to FXR. We next investigated the effects of performing site-directed mutations to convert the ADH1C IR1 element into the ADH1A IR1 element in the context of the of ~2.6 kb ADH1C promoter. In contrast to the wild-type, the activity of the construct bearing the mutated IR1 (pGL3-ADH1Cmut1A) was markedly increased by FXR (Fig. 5E ). Collectively, these findings indicate that ADH1A and ADH1B are direct target genes of FXR and that the IR1 elements located at their respective proximal promoters are essential for the response to FXR.
Binding Analysis of FXR to the IR1s in the ADH1A and ADH1B Promoters
To determine whether FXR-RXR heterodimers directly bind the IR1s identified in the proximal promoters of ADH1 genes, electrophoretic mobility shift analysis (EMSAs) were performed. Incubation of in vitro translated FXR and RXR together with radiolabeled doublestranded oligonucleotides containing the IR1 located at the proximal promoter of ADH1A or ADH1B resulted in a specific retarded complex (Fig. 6A, lanes 4 and 6, respectively) . In contrast, the probe containing the IR1 in the ADH1C promoter failed to form a specific DNA protein complex (Fig. 6A, lane 8 (Fig. 6B , lanes 5-7 and lanes 11-13), whereas no disappearance of the retarded complexes was appreciated when a mutated IR1 was used as a competitor (Fig. 6B, lanes 8-10) .
Activation of FXR Increases ADH1 Enzymatic Activity
Having shown that activation of FXR increases ADH1 mRNA and protein levels, we next investigated whether the activity of the enzyme was also increased. Exposure of Huh7 cells to CDCA or GW4064 resulted in an increase of alcohol dehydrogenase activity (Fig. 7A ). To confirm that such increase was dependent on FXR, we transfected Huh7 cells with FXR-specific or non-targeting siRNA prior to treatments with GW4064. As depicted in Fig. 7B , when FXR expression was silenced, the stimulatory effect of GW4064 on ADH activity is completely abolished. Thus, we conclude that FXR regulates not only ADH1 expression but also the overall cellular ADH activity.
DISCUSSION
The present study identifies the human ADH1A and ADH1B genes as direct targets of the bile acid-activated nuclear receptor FXR. The evidences for this finding are the following: a) the expression of ADH1A and ADH1B is induced in HepG2 cells, Huh7 cells, and primary human hepatocytes in response to natural and synthetic FXR ligands; b) overexpression of constitutively active FXR augments ADH1A and ADH1B mRNA levels; c) IR1 elements identified at the proximal promoters of ADH1A and ADH1B are able to confer FXR response and bind FXR-RXR heterodimers; d) alcohol dehydrogenase activity is increased upon FXR activation; e) silencing of FXR abolished the effects of FXR agonists on ADH1 expression and activity.
At the present time, the reason why FXR regulates ADH1 genes is not immediately obvious. Previous studies have shown that 3-dehydrogenation of iso bile acids is catalyzed by ADH1C isoenzyme (19, 20 ), yet we have failed to observe significant changes in ADH1C expression in response to FXR agonists. Moreover, although ADH1B has been shown to catalyze a step of bile acid synthesis (18) , it is counterintuitive to presume that this is the explanation for the FXR-dependent regulation of ADH1B given the inhibitory effects that FXR exerts on the biosynthesis of bile acids (10) . In fact, more recent reports have concluded that ADH1 activity may be dispensable for bile acid biosynthesis, since the bile acid pool is unchanged when class I ADH is absent (31) , and that mitochondrial CYP27 performs all steps in the formation of 3, 7, 12-trihydroxy-5-cholestanoic acid from the corresponding 3, 7, 12-triol (32, 33) .
Nevertheless, given the bile acid detoxifying role of FXR (16), we cannot exclude that the regulation of ADH1 genes by FXR responds to protective pathways whereby ADH1A and ADH1B isoenzymes metabolize yet unknown bile alcohols and/or bile acids to less toxic products. In agreement with this hypothesis, several bile alcohols and bile acids that are intermediates in the bile acid synthetic pathway have been identified as highly efficacious ligands for FXR (34) . Also in this regard, it is interesting to consider the sequential turn-on of ADH1 genes during liver development. Whereas ADH1A isoenzyme is found during early stages of fetal liver development and ADH1B appears at later fetal stages, ADH1C is only detected several months postnatally (4) . Therefore, it is tempting to speculate that the isoenzyme specific regulation by FXR that we observe may correspond to a mechanism of protection during fetal liver development. In this context, it is worth noting that fetal bile acid synthesis differs markedly from that of adult and "atypical" bile acids are found in human fetal bile. As an example, C-4 hydroxylated bile acids, which account for 5-15% of the total biliary bile acids of the fetus, are exclusive to early human development (35) . Hence, it will be of considerable interest for future liver development studies to determine whether human ADH1 isoenzymes metabolize fetal specific bile acids.
Strikingly, the FXR-dependent induction of class I ADH1 genes is species-specific, because rodent hepatic Adh1 mRNA levels did not increase after activation of FXR (Fig. 4) .
Such a species-dependent regulation has also been observed for other human FXR target genes, and primates. Several lines of evidence indicate that the first split was between ADH1C and the gene that gave rise ADH1B and ADH1A (43). The current findings that FXR induces ADH1A and ADH1B but not ADH1C correlates with this evolutionary mechanism that places ADH1C as the outgroup. Consequently, it is tempting to postulate that the FXR response appeared after the first split and before the split between ADH1A and ADH1B.
Inasmuch as ADH1 enzymes catalyze the rate-limiting steps of retinol and ethanol metabolism in humans (3, 17) , the current data suggest that the activation of FXR is likely to enhance the metabolism of retinol and ethanol. On the other hand, we did not observe a significant effect of FXR activators in the mRNA levels of CYP2E1, an enzyme that also contributes to ethanol metabolism in chronic alcohol ingestion. In addition, incubation of human cells with FXR agonists failed to increase ALDH1A1 or ALDH2 mRNA levels. Therefore, additional studies will be required to define whether treatments with FXR ligands might effectively modify ethanol metabolism in vivo.
In conclusion, our data reveal a direct stimulatory role for FXR on ADH1, which points to a possible involvement of ADH1 in bile alcohol and/or bile acid catabolism. Furthermore, the FXR-dependent activation of ADH1 also suggest a potential effect on ethanol metabolism that should be taken into account in future clinical trials with FXR modulators.
with cell culture experiments.
Financial support
Supported by grants from the Spanish government (SAF2008-04606) and the Catalan 
